Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PLM 102

Next Previous
Drug Profile

PLM 102

Alternative Names: PLD-102; PLM-102

Latest Information Update: 29 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PeLeMed
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-ret modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 24 Apr 2026 M.D. Anderson Cancer Center plans to initiate a phase I trial for Acute myeloid leukemia (Second-line therapy or greater) in the US (PO) (NCT07549464)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 20 Feb 2025 Phase-I clinical trials in Acute myeloid leukaemia in South Korea (PO), prior to February 2025 (PeLeMed pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top